might increase the endogenous anticoagulant activity as an endogenous regulatory mechanism after cerebral ischemia.
Levels of TIMP-1 were significantly increased in plasma samples from stroke patients as compared with controls. Generally, TIMPs inhibit active MMPs by forming noncovalent stoichiometric complexes within the catalytic site. Several recent reports suggest a role of TIMPs in brain and peripheral nerve injury and repair. TIMPs are induced after kainate-induced excitotoxic seizures in mice. 8 TIMP-1 mRNA expression is decreased 2 or 3 days after injury and remains elevated in areas where initial degeneration occurs. Furthermore, TIMP-1 is expressed by Schwann cells and macrophages after sciatic nerve injury in humans. 9 These studies indicate that TIMPs, by virtue of their ability to limit the extent of injury-induced matrix proteolysis, may be associated with the remodeling of neuronal circuits after injury. Brain microvascular endothelial cells upregulate TIMP-1 in response to a variety of cytokines, with the strongest effect exerted by the combination of IL-1␤ and TNF-␣. 10 Additionally, TIMP-1 blocks degradation of IL-1␤ by several MMPs. 11 These cytokines are implicated in neurodegeneration in the early phase of stroke and are frequently found in the plasma of stroke patients. Levels of TIMP-2 in stroke patients were not different from controls. TIMP-2, which is constitutively expressed, is not significantly influenced by cytokines and growth factors. 12 This further supports the hypothesis that TIMPs are upregulated in the context of cytokine expression after stroke. In an animal model of stroke, TIMP-2 inhibited MMP-2 activity and reduced proteolytic opening of the blood-brain barrier by MMP-2. 13 Therefore the absence of an increase of TIMP-2 in combination with upregulated MMP-9 could also contribute to an increased risk of hemorrhage after cerebral ischemia.
We did not observe differences in MMP-2 expression between stroke patients and controls. Increased levels of MMP-2 have been found after cerebral ischemia in human brain tissue 14 at 2 days after stroke, correlating with the poststroke time course of capillary remodeling.
Our findings suggest that there is a delicate change of the levels of matrix degrading proteins (MMPs) and their endogenous counterregulators (TIMPs) in the early phase after cerebral ischemia. Whether these changes contribute to tissue injury or are the result of ischemia needs to be investigated in prospective studies. 
Levels of MMP-2, MMP-8, MMP-9, TIMP-1, and TIMP-2 in the Plasma of Patients in the Early Phase of Cerebral Ischemia as Compared With Controls

Response
We very much appreciate the letter by Lorenzl et al regarding to the levels of matrix metalloproteinases (MMPs) in patients with ischemic stroke, as their data further support our own previously published results. 1 In a sample of 24 patients with a first episode of ischemic stroke, Lorenzl et al analyze the levels of MMP-2, MMP-9, and MMP-8 as well as the levels of MMP-inhibitors (TIMP-1 and TIMP-2). In accordance with our results, MMP-9 levels on admission are reported to be much higher in the only patient who subsequently developed hemorrhagic transformation of the ischemic tissue, whereas no differences are found between the levels in patients with ischemic stroke compared with control levels, a fact that may be indicating a specific role of MMP-9 in the development of hemorrhagic complications after cerebral ischemia. Levels of MMP-2 and TIMP-2 are also reported to be similar in patients and controls, whereas TIMP-1 levels are reported to be significantly higher in stroke patients. This is in agreement with previous experimental published data that demonstrate an early increase of TIMP-1, which appears at the time of maximal increase of MMP-9 in an attempt to avoid the blood-brain barrier opening, and a later increase of MMP-2 and TIMP-2 in the time course of molecules expression following cerebral ischemia at the time when the repair process begins. 2 To our knowledge, no previous data have been previously published about the levels of MMP-8 in cerebral ischemia, which are reported to be significantly lower in stroke patients compared with controls in the report of Lorenzl et al.
MMP release is regulated at the transcriptional level by cytokines and growth factors, which stimulate the synthesis and secretion of pro-MMPs and also their endogenous inhibitors, 3, 4 so MMP levels may be reflecting the degree of the inflammatory response secondary to different processes. Due to this fact, the control subjects in the Lorenzl et al letter might have not been appropriate, since they studied patients with headache and seizures, in whom an inflammatory reaction cannot be ruled out. A rapid increase of cytokines such as interleukin (IL)-1␤ and TNF-␣ has been reported in response to limbic seizures, 5 and higher levels of these cytokines have also been demonstrated in patients with some types of headache compared with healthy subjects. 6 Moreover, MMP-9 levels have also been reported to be increased after seizures. 7 Despite this fact, it is becoming increasingly clear that proteolytic enzymes participate in the pathophysiology of cerebral ischemia, although further and larger studies are still necessary to completely elucidate the role of MMPs and their inhibitors in acute human stroke.
